MX360595B - Terapia génica para la enfermedad de niemann-pick de tipo a. - Google Patents
Terapia génica para la enfermedad de niemann-pick de tipo a.Info
- Publication number
- MX360595B MX360595B MX2014005624A MX2014005624A MX360595B MX 360595 B MX360595 B MX 360595B MX 2014005624 A MX2014005624 A MX 2014005624A MX 2014005624 A MX2014005624 A MX 2014005624A MX 360595 B MX360595 B MX 360595B
- Authority
- MX
- Mexico
- Prior art keywords
- niemann
- gene therapy
- disease type
- pick disease
- mammal
- Prior art date
Links
- 208000035343 Infantile neurovisceral acid sphingomyelinase deficiency Diseases 0.000 title 1
- 201000000794 Niemann-Pick disease type A Diseases 0.000 title 1
- 208000007824 Type A Niemann-Pick Disease Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 108700019146 Transgenes Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 abstract 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un primer vector viral que comprende un transgen que codifica un inmunógeno; y un segundo vector viral que comprende un transgen que codifica el inmunógeno para uso en el tratamiento de transtornos de almacenamiento lisosomal con involucración del SNC, en donde: dicho primer vector viral está adaptado para ser administrable al tejido hepático de un mamífero, de tal modo que el cerebro del mamífero tolera el inmunógeno; y dicho segundo vector viral está adaptado para ser administrable subsecuentemente al cerebro de dicho mamífero, después de que dicho primer vector viral, que compren un transgen que codifica el inmunógeno, se ha expresado en el hígado del mamífero durante un tiempo efectivo para generar la tolerancia, y en donde el inmunógeno es la enzima defectiva asociada con la enfermedad de almacenamiento lisosomal que se está tratando.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77162806P | 2006-02-08 | 2006-02-08 | |
US77236006P | 2006-02-09 | 2006-02-09 | |
PCT/US2007/003388 WO2007092563A2 (en) | 2006-02-08 | 2007-02-08 | Gene therapy for niemann-pick disease type a |
Publications (1)
Publication Number | Publication Date |
---|---|
MX360595B true MX360595B (es) | 2018-11-09 |
Family
ID=38345806
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005624A MX360595B (es) | 2006-02-08 | 2007-02-08 | Terapia génica para la enfermedad de niemann-pick de tipo a. |
MX2018008355A MX2018008355A (es) | 2006-02-08 | 2008-08-07 | Terapia genica para la enfermedad de niemann-pick de tipo a. |
MX2018013684A MX2018013684A (es) | 2006-02-08 | 2008-08-07 | Terapia genica para la enfermedad de niemann-pick de tipo a. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008355A MX2018008355A (es) | 2006-02-08 | 2008-08-07 | Terapia genica para la enfermedad de niemann-pick de tipo a. |
MX2018013684A MX2018013684A (es) | 2006-02-08 | 2008-08-07 | Terapia genica para la enfermedad de niemann-pick de tipo a. |
Country Status (16)
Country | Link |
---|---|
US (3) | US20090117156A1 (es) |
EP (2) | EP3456331B1 (es) |
JP (2) | JP5706602B2 (es) |
AR (1) | AR059371A1 (es) |
BR (1) | BRPI0707590A2 (es) |
CY (1) | CY1121380T1 (es) |
DK (1) | DK1986661T3 (es) |
ES (1) | ES2700048T3 (es) |
HU (1) | HUE041928T2 (es) |
IL (2) | IL193165B (es) |
LT (1) | LT1986661T (es) |
MX (3) | MX360595B (es) |
PL (1) | PL1986661T3 (es) |
PT (1) | PT1986661T (es) |
SI (1) | SI1986661T1 (es) |
WO (1) | WO2007092563A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2394482T3 (es) | 2005-05-02 | 2013-02-01 | Genzyme Corporation | Terapia génica para trastornos de la médula espinal |
EP1879624B1 (en) | 2005-05-02 | 2011-09-21 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
PT2158322T (pt) | 2007-06-06 | 2017-08-09 | Genzyme Corp | Terapia genética para doenças do armazenamento lisossomal |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
EP2826860B1 (en) * | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
WO2012145646A1 (en) * | 2011-04-20 | 2012-10-26 | Miguel Sena-Esteves | Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis |
CN105377039A (zh) * | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
BR112017007737A2 (pt) | 2014-10-21 | 2018-01-30 | Univ Massachusetts | variantes de aav recombinantes e usos das mesmas |
JP6879486B2 (ja) * | 2015-03-17 | 2021-06-02 | フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel | Fviiiおよびfix用の最適化された肝臓特異的発現系 |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
EP3452104A1 (en) | 2016-04-15 | 2019-03-13 | The Trustees of The University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
MX2019003567A (es) | 2016-09-28 | 2019-12-02 | Cohbar Inc | Peptidos terapeuticos relacionados con mots-c. |
KR20190075964A (ko) | 2016-10-13 | 2019-07-01 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
AU2017355502B2 (en) * | 2016-11-04 | 2023-08-31 | The Children's Hospital Of Philadelphia | Gene transfer compositions, methods and uses for treating neurodegenerative diseases |
US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
WO2018237066A1 (en) * | 2017-06-20 | 2018-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CODON OPTIMIZED HUMAN NPC1 GENES FOR THE TREATMENT OF C1-TYPE NIEMANN-PICK DISEASE AND ASSOCIATED STATES |
EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
BR112020020195A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
SG11202009452WA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
CN113518784A (zh) | 2019-01-28 | 2021-10-19 | 科巴公司 | 治疗性肽 |
AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
EP3958912A4 (en) * | 2019-04-24 | 2023-02-22 | Oregon Health & Science University | PROMOTER SEQUENCE AND RELATED PRODUCTS AND THEIR USES |
TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療c型尼曼—匹克病之腺相關病毒載體 |
KR20230031329A (ko) * | 2020-06-30 | 2023-03-07 | 칠드런스 내셔널 메디컬 센터 | 골격 근섬유 복구를 개선하기 위한 재조합 인간 산성 스핑고미엘리나제의 용도 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
DE3424893A1 (de) | 1984-07-06 | 1986-02-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches silberhalogenidaufzeichnungsmaterial |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
US6114114A (en) | 1992-07-17 | 2000-09-05 | Incyte Pharmaceuticals, Inc. | Comparative gene transcript analysis |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
ATE314482T1 (de) | 1993-10-25 | 2006-01-15 | Canji Inc | Rekombinante adenoviren-vektor und verfahren zur verwendung |
PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
JPH10501686A (ja) * | 1994-04-13 | 1998-02-17 | ザ ロックフェラー ユニヴァーシティ | 神経系の細胞へのdnaのaav仲介送達 |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
ATE333893T1 (de) | 1997-10-29 | 2006-08-15 | Genzyme Corp | Gentherapie für gaucher-krankheit |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
US6582692B1 (en) * | 1999-11-17 | 2003-06-24 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
EP1261379A2 (en) * | 2000-02-17 | 2002-12-04 | Genzyme Corporation | Genetic modification of the lung as a portal for gene delivery |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2003231909A1 (en) * | 2002-06-14 | 2003-12-31 | Yeda Research And Development Co. Ltd. | Antigen-presenting cells for neuroprotection and nerve regeneration |
WO2004020600A2 (en) * | 2002-08-28 | 2004-03-11 | University Of Florida | Modified aav |
US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
-
2007
- 2007-02-08 LT LTEP07763560.5T patent/LT1986661T/lt unknown
- 2007-02-08 EP EP18190420.2A patent/EP3456331B1/en active Active
- 2007-02-08 ES ES07763560T patent/ES2700048T3/es active Active
- 2007-02-08 DK DK07763560.5T patent/DK1986661T3/da active
- 2007-02-08 PT PT07763560T patent/PT1986661T/pt unknown
- 2007-02-08 PL PL07763560T patent/PL1986661T3/pl unknown
- 2007-02-08 MX MX2014005624A patent/MX360595B/es unknown
- 2007-02-08 JP JP2008554342A patent/JP5706602B2/ja active Active
- 2007-02-08 AR ARP070100528A patent/AR059371A1/es not_active Application Discontinuation
- 2007-02-08 BR BRPI0707590-1A patent/BRPI0707590A2/pt not_active IP Right Cessation
- 2007-02-08 WO PCT/US2007/003388 patent/WO2007092563A2/en active Application Filing
- 2007-02-08 HU HUE07763560A patent/HUE041928T2/hu unknown
- 2007-02-08 EP EP07763560.5A patent/EP1986661B1/en active Active
- 2007-02-08 SI SI200732075T patent/SI1986661T1/sl unknown
-
2008
- 2008-07-31 IL IL193165A patent/IL193165B/en not_active IP Right Cessation
- 2008-08-07 MX MX2018008355A patent/MX2018008355A/es unknown
- 2008-08-07 MX MX2018013684A patent/MX2018013684A/es unknown
- 2008-08-07 US US12/187,844 patent/US20090117156A1/en not_active Abandoned
-
2013
- 2013-04-25 JP JP2013092907A patent/JP5881641B2/ja active Active
-
2018
- 2018-04-09 IL IL258587A patent/IL258587A/en unknown
- 2018-11-28 CY CY20181101265T patent/CY1121380T1/el unknown
-
2019
- 2019-08-19 US US16/544,735 patent/US20200080066A1/en not_active Abandoned
-
2023
- 2023-03-08 US US18/119,201 patent/US20230287366A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3456331B1 (en) | 2021-05-26 |
US20200080066A1 (en) | 2020-03-12 |
US20090117156A1 (en) | 2009-05-07 |
WO2007092563A2 (en) | 2007-08-16 |
CY1121380T1 (el) | 2020-05-29 |
JP5706602B2 (ja) | 2015-04-22 |
EP1986661B1 (en) | 2018-08-29 |
LT1986661T (lt) | 2018-12-10 |
EP1986661A2 (en) | 2008-11-05 |
EP1986661A4 (en) | 2012-04-25 |
PL1986661T3 (pl) | 2019-02-28 |
EP3456331A1 (en) | 2019-03-20 |
US20230287366A1 (en) | 2023-09-14 |
DK1986661T3 (da) | 2019-01-02 |
MX2018013684A (es) | 2021-06-15 |
JP2009526067A (ja) | 2009-07-16 |
IL258587A (en) | 2018-06-28 |
ES2700048T3 (es) | 2019-02-13 |
JP5881641B2 (ja) | 2016-03-09 |
SI1986661T1 (sl) | 2018-12-31 |
BRPI0707590A2 (pt) | 2011-05-10 |
JP2013166777A (ja) | 2013-08-29 |
WO2007092563A3 (en) | 2007-11-22 |
PT1986661T (pt) | 2018-12-05 |
MX2018008355A (es) | 2021-06-15 |
IL193165B (en) | 2018-04-30 |
HUE041928T2 (hu) | 2019-06-28 |
AR059371A1 (es) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX360595B (es) | Terapia génica para la enfermedad de niemann-pick de tipo a. | |
US20210283108A1 (en) | Method for treating neurodegenerative diseases | |
ES2897453T3 (es) | Aplicación de R-ketamina y sal de la misma como productos farmacéuticos | |
EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
HRP20171165T1 (hr) | Genska terapija za lizosomske bolesti nakupljanja | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MX2011013467A (es) | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). | |
UA104869C2 (uk) | Фармацевтичні композиції, що містять ліганди рецептора дофаміну | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
PE20081389A1 (es) | Uso de profarmacos de analogos de gaba para tratar enfermedades | |
MX339684B (es) | Metodos, compuestos, composiciones y vehiculos para suministrar el acido 3-amino-1-propanosulfonico. | |
UA115648C2 (uk) | Доставка терапевтичних агентів до цнс | |
WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
MX2013000321A (es) | Suministro al sistema nervioso central de agentes terapeuticos. | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
MX2007004051A (es) | Pi3-quinasas. | |
EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
MX2009003246A (es) | Análogos de ghrelina sustituidos en el terminal n. | |
WO2011119227A3 (en) | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |